Immunic, Inc.

NASDAQ:IMUX

Biotechnology

Healthcare
$7.52 -0.28%

-$0.04 today

Market cap
$102.61M
Beta
1.39
P/E (TTM)
-4.1
EPS (TTM)
-$3.46
52W Low $5.06High $15.77

Volume 0.17M

Average 0.27M

IMUX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Immunic, Inc.NASDAQ: IMUX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) growth accelerates

Q1 FY2026 weighted avg shares (diluted) of 30.14M shares rose 197.4% year over year, ahead of the +98.7% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 93.6% from the prior quarter. Over 3 fiscal years it compounded at +69.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +197.4% holds above the trailing-twelve-month pace of +98.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
30.14M+93.6% QoQ
Last fiscal yearDec 2025
15.57M+55.4% YoY
LTMMar 2026
19.58M+98.7% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+197.4%——
1 year+55.4%——
3-year CAGR+69.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
15.57M USD
Year-over-year change
+55.4%
4-year CAGR
+60.2%

Weighted Avg Shares (Diluted) vs competitors

How IMUX compares with its peers on the latest reported figures

  • IMUX's LTM Mar 2026 weighted avg shares (diluted) of 19.58M shares is the 8th highest of the 9 companies compared; the peer median is 55.89M shares.
  • Its year-over-year change of +98.7% is the 2nd highest of 9, against a peer median of +21.8%.
  • Over three fiscal years its annual growth of +69.8% compares with a peer median of +15.4%.
IMUX Competitors Peer median
Weighted Avg Shares (Diluted) for IMUX and competitors
Company Period LTM YoY 3-year CAGR
CBUSCibus, Inc.LTM Mar 2026301.04M +1164.8%-7.5%
VXRTVaxart, Inc.LTM Mar 2026232.46M +14.7%-22.1%
TCRXTScan Therapeutics, Inc.LTM Mar 2026129.84M +7.6%+75.4%
BMEABiomea Fusion, Inc.LTM Mar 202656.46M +55.6%+21.3%
RLMDRelmada Therapeutics, Inc.LTM Mar 202655.31M +82.9%+10.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 202652.9M +2.4%+4.8%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 202638.56M +2.3%+20.7%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
ACETAdicet Bio, Inc.LTM Mar 20267.26M +28.8%+39.0%
Peer median (excluding IMUX) 55.89M+21.8%+15.4%

Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development61.12M71.26M83.22M80.05M81.98M
Selling, General & Admin13.3M15.26M16.01M18.01M21.25M
Operating Expenses91.67M119.49M99.22M98.05M103.23M
Depreciation & Amortization85K77K111K134K168K
EBITDA(92.86M)(86.44M)(93.5M)(100.37M)(97M)
EBITDA Margin—————
Operating Income(91.67M)(119.49M)(99.22M)(98.05M)(103.23M)
Operating Margin—————
Interest Income66K1.04M3.08M3.39M1.04M
Interest Expense01.04M000
Other Income / Expenses(1.28M)(919K)5.61M(2.46M)6.06M
Income Before Tax(92.95M)(120.41M)(93.61M)(100.51M)(97.17M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(92.95M)(120.41M)(93.61M)(100.51M)(97.17M)
Net Margin—————
EPS (Basic)(39.20)(37.80)(21.10)(10.00)(6.24)
EPS (Diluted)(39.20)(37.80)(21.10)(10.00)(6.24)
Weighted Avg Shares2.37M3.18M4.43M10.02M15.57M
Weighted Avg Shares (Diluted)2.37M3.18M4.43M10.02M15.57M

Immunic, Inc.

NASDAQ:IMUX

Intrinsic Alpha fair value

Locked

Current Price

$7.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.